Karuna Therapeutics – Trial Evaluating KarXT in Schizophrenia

Dr. Andrew Miller is the Founder and Chief Operating Officer of Karuna Therapeutics and  primary inventor of the company’s lead product candidate, KarXT (xanomeline-trospium). Dr. Miller  discusses this  investigational treatment, which offers a potential new approach to treating schizophrenia and other neuropsychiatric conditions, including psychosis in Alzheimer’s disease, by way of its unique differentiated mechanism of action that does not rely on targeting dopaminergic or serotonergic pathways, as  currently available treatments do. If successfully developed and approved, KarXT has the potential to usher in the newest generation of antipsychotics for patients and ultimately change the treatment paradigm as we know it.  

Dr. Andrew Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. He served as a member of Karuna’s board of directors from April 2012 to March 2019. From August 2008 to July 2016, Dr. Miller held several positions at PureTech Health plc, last serving as a Vice President, Venture Partner, and served as Chief Operating Officer of Tal Medical, and the acting Chief Operating Officer of Entrega, Inc. He is currently a member of the board of directors of Entrega, Inc.

Dr. Miller received his bachelor’s degree in Chemical Engineering from the University of Illinois with highest honors, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.